AEON Biopharma, Inc. Cash Flow-to-Debt Ratio
AEON Biopharma, Inc. cash flow-to-debt ratio. AEON Biopharma, Inc. (AEON) has a Cash Flow-to-Debt Ratio of -0.09x as of September 2025, meaning its operating cash flow of $-2.60 Million could theoretically repay 0% of its total liabilities ($28.61 Million) in one year. Check AEON Biopharma, Inc. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of AEON Biopharma, Inc. (2019–2024)
Cash flow-to-debt ratio of AEON Biopharma, Inc. from 2019 to 2024. Historical debt coverage capacity for AEON Biopharma, Inc. across 6 annual periods. Also explore AEON shareholders equity momentum to track the company's year-over-year net asset growth rate.
AEON Biopharma, Inc. Cash Flow-to-Debt Ratio by Year (2019–2024)
AEON Biopharma, Inc. cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for AEON Biopharma, Inc.. For the full cash flow conversion analysis, see AEON cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.64x | $-20.29 Million | $31.71 Million | ▼ -113.9% |
| 2023 | -0.30x | $-47.83 Million | $159.89 Million | ▼ -136.4% |
| 2022 | -0.13x | $-35.58 Million | $281.19 Million | ▼ -2.5% |
| 2021 | -0.12x | $-28.43 Million | $230.26 Million | ▼ -192.9% |
| 2020 | -0.04x | $-9.46 Million | $224.45 Million | ▲ +83.0% |
| 2019 | -0.25x | $-44.73 Million | $180.22 Million | — |